Literature DB >> 24302010

GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle.

Kim A Sjøberg1, Jens J Holst, Stephen Rattigan, Erik A Richter, Bente Kiens.   

Abstract

The insulinotropic gut hormone glucagon-like peptide-1 (GLP-1) has been proposed to have effects on vascular function and glucose disposal. However, whether GLP-1 is able to increase microvascular recruitment (MVR) in humans has not been investigated. GLP-1 was infused in the femoral artery in overnight-fasted, healthy young men. Microvascular recruitment was measured with real-time contrast-enhanced ultrasound and leg glucose uptake by the leg balance technique with and without inhibition of the insulinotropic response of GLP-1 by coinfusion of octreotide. As a positive control, MVR and leg glucose uptake were measured during a hyperinsulinemic-euglycemic clamp. Infusion of GLP-1 caused a rapid increase (P < 0.05) of 20 ± 12% (mean ± SE) in MVR in the vastus lateralis muscle of the infused leg after 5 min, and MVR further increased to 60 ± 8% above preinfusion levels by 60 min infusion. The effect was slightly slower but similar in magnitude in the noninfused contralateral leg, in which GLP-1 concentration was within the physiological range. Octreotide infusion did not prevent the GLP-1-induced increase in MVR. GLP-1 infusion did not increase leg glucose uptake with or without octreotide coinfusion. GLP-1 infusion in rats increased MVR by 28% (P < 0.05) but did not increase muscle glucose uptake. During the hyperinsulinemic clamp, MVR increased ∼40%, and leg glucose uptake increased 35-fold. It is concluded that GLP-1 in physiological concentrations causes a rapid insulin-independent increase in muscle MVR but does not affect muscle glucose uptake.

Entities:  

Keywords:  capillary recruitment; incretin hormones; insulin; microcirculation

Mesh:

Substances:

Year:  2013        PMID: 24302010      PMCID: PMC3923091          DOI: 10.1152/ajpendo.00283.2013

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  39 in total

1.  Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.

Authors:  H A Golpon; A Puechner; T Welte; P V Wichert; C O Feddersen
Journal:  Regul Pept       Date:  2001-12-15

2.  Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

Authors:  D A D'Alessio; S E Kahn; C R Leusner; J W Ensinck
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

3.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

Authors:  M Gutniak; C Orskov; J J Holst; B Ahrén; S Efendic
Journal:  N Engl J Med       Date:  1992-05-14       Impact factor: 91.245

4.  Glucose clamp technique: a method for quantifying insulin secretion and resistance.

Authors:  R A DeFronzo; J D Tobin; R Andres
Journal:  Am J Physiol       Date:  1979-09

5.  Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum.

Authors:  Lene Hansen; Bolette Hartmann; Hitoshi Mineo; Jens J Holst
Journal:  Regul Pept       Date:  2004-04-15

6.  Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences.

Authors:  Y Wei; S Mojsov
Journal:  FEBS Lett       Date:  1995-01-30       Impact factor: 4.124

7.  Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.

Authors:  A Hvidberg; M T Nielsen; J Hilsted; C Orskov; J J Holst
Journal:  Metabolism       Date:  1994-01       Impact factor: 8.694

8.  Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.

Authors:  C Orskov; L Rabenhøj; A Wettergren; H Kofod; J J Holst
Journal:  Diabetes       Date:  1994-04       Impact factor: 9.461

9.  Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin.

Authors:  M A Vincent; E J Barrett; J R Lindner; M G Clark; S Rattigan
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-07       Impact factor: 4.310

10.  Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome.

Authors:  Manfredi Tesauro; Francesca Schinzari; Angelo Adamo; Valentina Rovella; Francesca Martini; Nadia Mores; Angela Barini; Dario Pitocco; Giovanni Ghirlanda; Davide Lauro; Umberto Campia; Carmine Cardillo
Journal:  Diabetes Care       Date:  2012-10-15       Impact factor: 19.112

View more
  14 in total

1.  Glucose-dependent insulinotropic polypeptide directly induces glucose transport in rat skeletal muscle.

Authors:  Laelie A Snook; Emery M Nelson; David J Dyck; David C Wright; Graham P Holloway
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-06-03       Impact factor: 3.619

2.  Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance.

Authors:  Kim A Sjøberg; Stephen Rattigan; Jacob F Jeppesen; Anne-Marie Lundsgaard; Jens J Holst; Bente Kiens
Journal:  J Physiol       Date:  2015-03-19       Impact factor: 5.182

3.  Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance.

Authors:  Nasui Wang; Alvin W K Tan; Linda A Jahn; Lee Hartline; James T Patrie; Shaoda Lin; Eugene J Barrett; Kevin W Aylor; Zhenqi Liu
Journal:  Diabetes Care       Date:  2019-12-30       Impact factor: 19.112

Review 4.  Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.

Authors:  Junfeng Li; Juan Zheng; Susanne Wang; Harry K Lau; Ali Fathi; Qinghua Wang
Journal:  Front Physiol       Date:  2017-01-30       Impact factor: 4.566

5.  GLP-1 and Insulin Recruit Muscle Microvasculature and Dilate Conduit Artery Individually But Not Additively in Healthy Humans.

Authors:  Alvin W K Tan; Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; James T Patrie; Kevin W Aylor; Ananda Basu; Zhenqi Liu
Journal:  J Endocr Soc       Date:  2018-01-22

6.  Acute effects of glucagon-like peptide-1, GLP-19-36 amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers.

Authors:  Lasse Bremholm; Ulrik B Andersen; Mads Hornum; Linda Hilsted; Simon Veedfald; Bolette Hartmann; Jens Juul Holst
Journal:  Physiol Rep       Date:  2017-02

7.  Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men.

Authors:  Ali Asmar; Meena Asmar; Lene Simonsen; Sten Madsbad; Jens J Holst; Bolette Hartmann; Charlotte M Sorensen; Jens Bülow
Journal:  Physiol Rep       Date:  2017-02

Review 8.  DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.

Authors:  Jianqiang Zhang; Qiuyue Chen; Jixin Zhong; Chaohong Liu; Bing Zheng; Quan Gong
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

9.  GIP-induced vasodilation in human adipose tissue involves capillary recruitment.

Authors:  Meena Asmar; Ali Asmar; Lene Simonsen; Flemming Dela; Jens Juul Holst; Jens Bülow
Journal:  Endocr Connect       Date:  2019-06       Impact factor: 3.335

10.  Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.

Authors:  Myo Myo Aung; Kate Slade; Leighton A R Freeman; Katarina Kos; Jacqueline L Whatmore; Angela C Shore; Kim M Gooding
Journal:  Diabetologia       Date:  2019-06-16       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.